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Hemorrhagic diseaseSimian Hemorrhagic Fever Virus (SHFV) has caused sporadic outbreaks of hemorrhagic fevers in macaques at pri-
mate research facilities. SHFV is a BSL-2 pathogen that has not been linked to human disease; as such, investigation
of SHFV pathogenesis in non-human primates (NHPs) could serve as amodel for hemorrhagic fever viruses such as
Ebola, Marburg, and Lassa viruses. Here we describe the pathogenesis of SHFV in rhesus macaques inoculated with
doses ranging from50 PFU to 500,000 PFU. Disease severitywas independent of dosewith an overall mortality rate
of 64%with signs of hemorrhagic fever andmultiple organ system involvement. Analyses comparing survivors and
non-survivorswere performed to identify factors associatedwith survival revealing differences in the kinetics of vi-
remia, immunosuppression, and regulation of hemostasis. Notable similarities between the pathogenesis of SHFV in
NHPs and hemorrhagic fever viruses in humans suggest that SHFV may serve as a suitable model of BSL-4
pathogens., NIAID/EVPS, Bldg 33Rm2E19A,
son).
nc.Published by Elsevier Inc.Introduction
The causative agents of viral hemorrhagic fevers (VHF) that affect
humans are RNA viruses from the families Filoviridae, Arenaviridae,
Bunyaviridae, and Flaviviridae including Ebola, Marburg, Lassa, Rift Valley
Fever, Crimean–Congo Hemorrhagic Fever, and Omsk Hemorrhagic
Fever viruses (Feldmann and Geisbert, 2011; Keshtkar-Jahromi et al.,
2011; Paragas and Geisbert, 2006; Peters et al., 1989; Ruzek et al.,
2010). Because of the extrememorbidity associatedwith these emerging
viruses and the concern that one or more may be used as bioterrorism
agents, efforts to further our understanding of disease pathogenesis
and to identify countermeasures have intensiﬁed.While numerous stud-
ies have deﬁned the clinical, virological, immunological, and pathological
manifestations of hemorrhagic fever viruses using non-human primate
(NHP) models (Geisbert et al., 2003a; Jaax et al., 1995; Johnson et al.,1995; Paragas and Geisbert, 2006; Peters et al., 1989), the viral and
host molecular mechanisms that control disease severity and outcome
remain largely unknown. Furthermore, no licensed therapeutic treat-
ments exist for any VHF. A better understanding of the mechanisms as-
sociated with VHF outcome would facilitate the investigation of
therapeutic agents. Identiﬁcation of broad-spectrum treatments target-
ing common viral or host factors is most desirable because the develop-
ment of individual therapies for each VHF is hindered by the sporadic
nature of the outbreaks and the limited commercial viability of such
products.
The necessity for high containment laboratories, for instance, bio-
safety level- (BSL-) 3 or 4, complicates the investigation of these VHF
pathogens. Alternatively, a virus that produces similar disease in
NHPs that can be studied under BSL-2 conditions would facilitate
studies of VHF viruses by virtue of broader access to the scientiﬁc
community. SHFV in NHPs might serve as an ideal model for human
viral hemorrhagic fevers because SHFV 1) has never been associated
with human disease, 2) is a biosafety level BSL-2 pathogen, and 3)
has clinical manifestations similar to other hemorrhagic fever viruses.
SHFV is an arterivirus that was ﬁrst identiﬁed in 1964 as the causa-
tive agent during an outbreak of hemorrhagic disease in Asian origin
Table 1
Survival, viremia, and incidence of secondary bacterial infection by dose.
Dose
(PFU)
% Moribund
(no. moribund/
total no.)
Mean day of
moribund
endpoint
(range)
Mean peak
viremia
Proportion of
non-survivors
that developed
bacteremiaa
(log10PFU/ml)
(range)
50 66 (2/3) 10.5 (5–16) 5.9 (0.0–6.1) 1/2
500 66 (2/3) 17.0 (15–19) 5.8 (4.7–6.2) 2/2
5000 66 (4/6) 13.5 (9–16) 5.7 (2.8–6.4) 2/4
50,000 75 (6/8) 9.3 (9–16) 5.5 (2.8–6.1) 5/6
500,000 40 (2/5) 12.0 (8–16) 4.7 (2.5–5.0) 2/2
a Bacteremia was deﬁned as positive by blood culture, presence of abscesses at nec-
ropsy, or presence of bacteria in multiple organs during histopathological examination.
130 R.F. Johnson et al. / Virology 421 (2011) 129–140macaques that occurred at both the National Institutes of Health (NIH,
Bethesda, MD) (Allen et al., 1968; Palmer et al., 1968; Tauraso et al.,
1968) and the Sukhumi Institute of Experimental Pathology and Thera-
py in the former USSR (Lapin and Shevtsova, 1971; Shevtsova, 1969b;
Shevtsova and Krylova, 1971b). Macaques from both institutes were ac-
quired from the same region of India andhousedwith African origin pri-
mates including patas monkeys, baboons, and African green monkeys
(Palmer et al., 1968; Shevtsova, 1969b). During the Sukhumi outbreak,
the case fatality rate was 100% over 2 months (Lapin and Shevtsova,
1971; Shevtosova et al., 1975) with disease presenting as a hemorrhagic
diathesis and acute diffuse encephalomyelitis (Shevtsova and Krylova,
1971b). During theNIH outbreak, the route of transmissionwas thought
to be iatrogenic: needles that were used for tattooing and tuberculosis
testing were shared between the African origin primates and the
macaques (Allen et al., 1968; Palmer et al., 1968; Tauraso et al., 1968).
Macaques developed high fevers and hemorrhagic diathesis but not
acute diffuse encephalomyelitis that was observed at Sukhumi (Allen
et al., 1968; Shevtsova and Krylova, 1971a). Mortality occurred in 233
of 1029macaques in affected rooms over a 2 month period. Initial char-
acterization suggested that all infected NHPs succumbed to disease.
However, follow up experiments indicated that macaques can develop
asymptomatic infection. Speciﬁcally, blood and tissue from an asymp-
tomatic survivor successfully induced a viral hemorrhagic fever in
macaques not associated with the initial outbreak (Palmer et al., 1968).
Sporadic SHFV outbreaks of iatrogenic origin have occurred since
1964 with mortality rates reported varying from 11% to as high as
100% (Gravell et al., 1986; London, 1977; Palmer et al., 1968; Tauraso
et al., 1970). During SHFV outbreaks in 1972 and 1989 the virus was
thought to be spread by both direct and indirect contact between
macaques (London, 1977; Renquist, 1990). In the 1989 Ebola-Reston
outbreak, SHFV was found in 19 of 49 Ebola-Reston positive macaques
that succumbed to hemorrhagic fever (Dalgard et al., 1992).
Analysis of SHFV outbreaks and limited experimental infection of ma-
caques identiﬁed common clinical signs including fever, mild facial ery-
thema, and edema as early as 48–72 h post-infection (Abildgaard et al.,
1975; Gravell et al., 1986; London, 1977; Palmer et al., 1968). Clinical
signs indicative of initial infection developedwithin 72 h post-inoculation
and included depression and petechial rash (Palmer et al., 1968). As the
disease progressed,macaques developed facial edema, cyanosis, anorexia,
adipsia, epistaxis, emesis, dehydration, melena, hematomata, retrobulbar
hemorrhage and hematologic signs of coagulopathy (Abildgaard et al.,
1975; Allen et al., 1968; Gravell et al., 1986; London, 1977; Palmer et al.,
1968; Shevtsova, 1969a; Shevtsova and Krylova, 1971a; Tauraso et al.,
1968). Clinically, SHFV-infected macaques developed increased activated
partial thromboplastin time (aPTT) and prothrombin time (PT), de-
creased hematocrit, variations in both complete blood count (CBC) pa-
rameters and degrees of thrombocytopenia (Palmer et al., 1968). Most
animals succumbed to infection within 10 to 15 days after initial onset
of disease.
The primary purpose of this study was to further investigate SHFV
as a BSL-2 model of viral hemorrhagic fever, and a secondary goal was
to identify factors that were associated with lethal disease. We dis-
covered that disease severity was not associated with dose, with an
overall mortality rate of 64%, although statistical power was limited
due to group size. Infected NHPs developed disease involving multi-
ple organ systems including the mononuclear phagocyte, circulatory,
lymphoid, renal, and hepatic systems. We compared survivors to non-
survivors to help identify clinical features of lethal disease and
markers that may predict outcome and provide targets for clinical
treatment and developing therapeutic options for other VHFs. Our
comparison of survivors and non-survivors revealed different kinetics
of viremia, varying severity and kinetics of immunosuppression, and
dysregulation of hemostasis. Backwards matched longitudinal analy-
sis (Dodd et al., in preparation) associated increased AST, ALP, ALT,
MCP-1, aPTT and IL-6 concentrations, decreases in ALB, and increased
aPTT with lethal disease.Results
Clinical outcome of SHFV infection
Five groups of rhesus macaques were inoculated intramuscularly
with increasing doses of SHFV from 50 to 500,000 PFU and were moni-
tored daily for clinical signs and periodically for physiological, virologi-
cal, and immunological parameters. The initial goal of these studies was
to identify a uniformly lethal dose for SHFV in rhesus macaques. Three
independent studies were performed. The ﬁrst study was a pilot study
consisting of 3 NHPs that were given 5000 PFU of SHFV, and the second
study was a dose ranging study with 4 groups of 3 NHPs which were
given 50, 500, 5000, or 50,000 PFU of SHFV. No dose response was
observed in the second study, so a third study was performed with 2
groups of 5 NHPs at 50,000 PFU and 500,000 PFU. Table 1 describes
mortality rates and viremia by dose; no differences in mortality by
dose or gender were observed, therefore comparisons between survi-
vors and non-survivors were used to evaluate factors that may affect
lethal outcome. All NHPs developed clinical signs of severe disease; six-
teen of the 25 challenged NHPs progressed to established endpoint cri-
teria (see Materials and methods) and were euthanized.
The most common clinical signs of disease were weight loss (as
deﬁned by 10% or greater decrease in bodyweight fromD0), dehydration,
edema, lymphadenopathy, petechial rash, and splenomegaly (Table 2).
Less common or transient signs were diarrhea, melena, epistaxis, weak-
ness, depression, gingival hemorrhage, and dyspnea. Hematuria was fre-
quently observed at necropsy (15 of 25 animals), and proteinuria was
observed in all non-survivors. Hematuria and proteinuria were the only
clinical signs associated with mortality (p=0.0081, and pb0.0001
respectively by Fisher's Exact Test). Common gross necropsy ﬁndings
included myocardial, pyloric junction, and terminal colon hemorrhage,
ﬁbrinous exudates in the lungs and heart, generalized edema, hepatic
necrosis, renal necrosis, splenomegaly and bacterial abscesses (Table 3).
SHFV induces a consumption coagulopathy that is consistent with a
hemorrhagic disease
Hematology supported a consumption coagulopathy as evidenced
by increases in activated partial thromboplastin time (aPTT) and pro-
thrombin time (PT), as well as decreases in hematocrit (HCT), hemoglo-
bin (HGB), and platelet counts (Fig. 1). For non-survivors, mean peak
elevations for aPTT and PT, and decreases for HCT, HGB, and platelet
counts occurred at days 9 (77.1 s), 9 (18.7 s), 11 (25.2%), 12 (93 g/L),
and 9 (119 cells×103/ml), respectively. For survivors, mean elevation
peaks for aPTT, PT, and decreases for HCT, HGB, and platelet counts
occurred at days 9 (66.1 s), 9 (18.9 s), 15 (23.8%), 15 (89 g/L), and 17
(134 cells×103/mL), respectively. The presence of ﬁbrin degradation
products (FDP), a characteristic of consumption coagulopathy, was
observed in 10/10 NHPs (4 survivors and 6 non-survivors) that com-
prised the third experiment (data not shown). FDP was detectable in
surviving NHPs by day 6 post inoculation and by day 4 post inoculation
in non-surviving NHPs. The concentrations of FDP were higher in non-
Table 2
Summary of clinical ﬁndings.a
Clinical sign Survivors
(incidence (%))
Mean days
observed
Non-survivors
(incidence (%))
Mean days
observed
Signiﬁcant difference in
incidence by Fisher's
Exact Test (p-value)
Dehydration 9/9 (100%) 6–16 16/16 (100%) 6.7–11.5 1.0000
Facial and/or scrotal edema 5/9 (56%) 7.5–16.5 11/16 (69%) 9.8–9.6 0.6707
Hematuriab 4/9 (44%) 11/11 (100%) 0.0081
Lymphadenopathy 7/8 (88%) 3.8–26 15/16 (94%) 4.3–11.5 1.000
Nares and perineum
hemorrhagec
2/9 (22%) 3/16 (19%) 1.000
Petechiation of skin 5/9 (56%) 7.6–11.6 10/16 (63%) 9.8–10.8 1.000
Proteinuriab 0/9 (0%) 11/11 (100%) b0.0001
Splenomegaly 3/9 (33%) 15.6–17.3 8/16 (50%) 7.6–13.1 0.6766
Weight Lossd 1/9 (11%) 21–36 10/16 (63%) 5–11.4 0.0330
a Criteria evaluated at each physical examunless otherwise noted andwas included if observed at any physical exam. For a fewNHPs, sample collectionmay have been incomplete and
was excluded for analysis as indicated by a lower denominator.
b Determined at necropsy.
c Not continually sustained.
d Weight loss was deﬁned as 10% or greater decrease from Day 0.
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(BMLA) comparing survivors and non-survivors indicated that increased
AUC and rate of change of aPTT was associated with lethality (AUC
p=0.0020, rate of change p=0.0249, and peak value p=0.0744).
Changes in PT, HCT, HGB and platelet concentration did not differ signif-
icantly between survivors and non-survivors.
Increased serum concentrations of AST, ALP, and ALT and decreases in
ALB were associated with lethal disease
Elevations in the concentrationsof AST, ALP, andALT anddecreases in
ALB concentrationswere observed between survivors and non-survivors
(Fig. 2) and statistically associated with lethal disease by backwards
matched longitudinal analysis. For non-survivors, mean peak concentra-
tions of AST, ALP, and ALT and peak decrease in ALB occurred at days 10
(1127 g/L), 10 (652 g/L), 9 (156 g/L), and 13 (1.7 g/L), respectively. For
survivors, mean peak concentrations of AST, ALP, ALT and peak decrease
in ALB occurred at days 8 (408 g/L), 10 (543 g/L), 15 (92 g/L), and 13
(2.3 g/L), respectively. Comparisons of concentrations of AST between
survivors and non-survivors using BMLA indicated that increased AUC
(p=0.0014), rate of change (p=0.0012), and peak value (p=0.0002),
were associated with lethal disease. The AUC analysis of ALP indicated
that increasedALPwas associatedwith lethal disease (p=0.0225). Addi-
tionally, rate of change of ALT (p=0.0190) and ALB (p=0.0073) were
associated with lethal disease.Table 3
Summary of gross pathological ﬁndings.a
Clinical sign Survivors
(incidence (%))
Non-survivors
(incidence (%))
Signiﬁcant difference in
incidence by Fisher's
Exact Test (p-value)
Bacterial Abscesses 1/9 (11%) 3/16 (19%) 1.0000
Myocardial
hemorrhage
1/9 (11%) 8/16 (50%) 0.0875
Pyloric junction
hemorrhage
0/9 (0%) 4/16 (25%) 0.2601
Splenomegalyb 2/9 (22%) 7/12 (58%) 0.1842
Terminal colon
hemorrhage
1/9 (11%) 9/16 (56%) 0.0405
a Criteria evaluated at gross necropsy of all subjects. Survivors were necropsied at
end of study on day 36.
b Splenomegaly based upon spleen weight as a twofold change in spleen mass as a
percentage of body weight at necropsy using the standard of Davies and Morris
(Davies and Morris, 1993).Immunosuppression is common in SHFV-infected NHPs
Immunosuppression was deﬁned as a 20% or greater decrease in cell
count based on CBC/Diff analysis. Results, summarized in Table 4, dem-
onstrate that leukopenia, lymphocytopenia,monocytopenia, and neutro-
peniawere prevalent in both survivors and non-survivors, and therewas
no indication of statistically relevant differences. However, monocytope-
nia occurred with twofold greater incidence (88%) in non-survivors
when compared to survivors (44%) but was not supported by Fisher's
Exact Test (p=0.0581). Monocytopenia was also observed earlier in in-
fection with a 7 day duration frommedian days 2 to 9 for non-survivors.
41.7% of surviving NHPs demonstrated a monocytopenia with a later
onset and duration occurring between days 4 and 16. Surprisingly, neu-
tropeniawasmore common and severe in survivingNHPs, but the differ-
ence in incidence and severity was not supported by Fisher's Exact Test
(p=0.2077). Neutropenia in survivors lasted for 18 days with reduc-
tions from 60.1 to 87.1%. Fewer non-surviving NHPs developed neutro-
penia with a mean duration of 7 days and ranges from 42.3 to 94.0%
reduction. Leukopenia and lymphocytopenia demonstrated little differ-
ence between survivors and non-survivors.
Plaque reduction neutralizing titer50 (PRNT50) indicates that NHPs
developed a variable antibody response
Although, NHPs became immunosuppressed they were able to
develop a neutralizing antibody response as shown in Fig. 3. PRNT50
indicated that 13 of 16 non-surviving NHPs developed neutralizing
antibody titers of 1:160 or greater by average day 9.5 post-inoculation.
Eight of 9 surviving NHPs developed neutralizing antibody titers of
1:160 or greater by average day 9.8. Changes in the peripheral blood
mononuclear cell populations and speciﬁc T-cell responses were not
measured.
MCP-1 and IL-6 are elevated in non-surviving NHPs
Simian hemorrhagic fever virus-infected NHPs typically mounted a
pro-inﬂammatory cytokine response. Of the 24 cytokines and chemo-
kines measured, only IL-1ra, IL-6, IL-8, IL-18, IFNγ, RANTES, MCP-1, and
VEGF increased 2-fold above baseline values andwere included for anal-
ysis. These data are summarized in Table 5. Backwardsmatched longitu-
dinal analyseswere performed on these selected cytokines and indicated
that MCP-1 and IL-6 were associated with lethal disease. MCP-1 proﬁles
were elevated for non-survivors over survivors for all 3 comparisons but
was suggestive of statistically signiﬁcant differences for only AUC (AUC
p=0.0285, rate of change p=0.1450, and peak value p=0.0538). IL-6
A BaPTT PT
C DHCT
E
HGB
Platelets
Fig. 1. Hematology supports an SHFV induced consumption coagulopathy. Longitudinal analysis of the daily averages from time of inoculation to study end. The red line represents
the daily average of survivors, the black line represents the daily average of non-survivors, data points represent individual NHPs.
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statistically signiﬁcant differences for only AUC (AUC p=0.0485, rate
of change p=0.0577, and peak value p=0.1074).
Histopathological analysis supports coagulopathy in SHFV infected
animals
Major histopathological ﬁndings and incidence within groups are
shown in Table 6. Histopathological examination of tissues from
non-surviving NHPs (16/25) demonstrated myocarditis (Fig. 4A),
necrotizing hepatitis (Fig. 4B), interstitial nephritis (Fig. 4C), pulmo-
nary edema and ﬁbrin thrombi (Fig. 4D), thymic necrosis with dystro-
phic mineralization (Fig. 5A), lymphadenitis (Fig. 5B), and necrotizing
splenitis (Fig. 5C). Twelve of 16 non-survivors developed septicemia
characterized by suppurative hepatitis, thyroiditis, orchitis (Fig. 4E),
encephalitis, pleuropneumonia with intralesional bacteria, and bonemarrow atrophy and necrosis. Septicemia was further conﬁrmed by
culturing Streptococcus. sp and Staphylococcus. sp from the blood of
non-survivors (Table 1). Major histopathologic changes in the survi-
vors (9/25) included interstitial pneumonia with ﬁbrosis, lymphoid
hyperplasia, interstitial nephritis, non-suppurative meningoencepha-
litis and myelitis (Fig. 6A). Immunohistochemical analysis of the
spleen and brain revealed positive staining for viral antigen in splenic
macrophages (Fig. 5D) and neuronal cell bodies, astrocytes, glial cells,
and encephalitic lesions (Fig. 6B). The incidence of bacteremia,
lymphadenitis, lymphoid depletion and lymphocytolysis of lymph
nodes, splenitis with lymphoid depletion, and thymocyte depletion
with necrosis and dystrophic mineralization was more common in
non-survivors than survivors (Fisher's Exact Test; p=0.0036,
pb0.0001, pb0.0001, and pb0.0001 respectively). Lymphoid hyper-
plasia within the spleen and lymph nodes occurred with greater inci-
dence in survivors (pb0.0001 and pb0.0001) (Table 6).
C D
A BAST ALP
ALBALT
Fig. 2. Serum chemistry values associated with lethality. Longitudinal analysis of the daily averages from time of inoculation to study end. Data points represent individual NHPs, the
red line represents the daily average of survivors; the black line represents the daily average of the non-survivors.
Table 4
Immunosuppression in SHFV-infected macaques.
Immunosuppressiona Survivors Non-survivors Signiﬁcant difference in
incidence by Fisher's
Exact Test (p-value)
Incidence Mean days of suppression
(days post inoculation)
% reduction
(range)
Incidence Mean days of suppression
(days post inoculation)
% reduction
(range)
Leukopenia 7/9 (78%) 4–12 60.2 11/16 (69%) 4–8 47.1 1.0000
(36.4–79.0) (20–79)
Lymphocytopenia 7/9 (78%) 2–10 62.8 12/16 (75%) 2–11 67.1 1.0000
(21–79) (50–82)
Monocytopenia 4/9 (44%) 4–16 67.7 14/16 (88%) 2–9 71.6 0.0581
(31.3–87.5) (47.1–90.3)
Neutropenia 7/9 (78%) 4–16 71.9 7/16 (44%) 4–16 65.5 0.2077
(60.1–87.1) (42.3–94.0)
a Immunosuppression deﬁned by 20% or greater reduction in cell number post-inoculation.
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macrophages are targeted by SHFV
Evaluation of the spleen revealed endothelial cell degeneration and
necrosis as evidenced by marked cytoplasmic vacuolation, high ampli-
tude mitochondrial swelling, loss of organelles, irregular chromatin
clumping and fragmentation, and disintegration of the nuclear and plas-
ma membranes (Fig. 7A). Medium electron dense paracrystalline arrays
of viral proteinwere commonly foundwithin dilated endoplasmic reticu-
lum of degenerate endothelial cells and macrophages (Fig. 7B). Rarely,
viral particles were seen within macrophages (Fig. 7C). Viral protein
was found within degenerate sinusoidal endothelial cells and macro-
phages in the liver (data not shown). In many areas throughout the
liver, endothelial cells were detached from the basement membrane, cel-
lular debrisﬁlled the lumina, and theperivascular adventitiawasmarked-
ly expanded by abundant electron lucent ﬁnely granular acellular
material (edema). Lymph node examination further supported viral rep-
licationwithinmacrophages as large paracrystalline arrays of viral proteinwere commonly found intracytoplasmically (data not shown). Evaluation
of the cerebrum also supports endothelial cells as a target cell type be-
cause all other cell types present appeared normal with only endothelial
cells demonstrating paracrystalline arrays of viral protein (Fig. 7D).
Viral load in tissues supports that SHFV targets the lymphoid, immune,
circulatory and hematopoietic systems
Viremia was higher and was present longer in non-surviving NHPs
when compared to surviving NHPs (Fig. 8A). Viremia could not be
detected past day 10 post-inoculation in surviving NHPs, and survivors
had a mean peak viremia of 4.79 log10 PFU/ml that occurred on day 6
post inoculation. Mean peak viremia for non-survivors was 5.66 log10
PFU/ml and occurred on day 7. There was no statistical evidence of an
association between increased viremia and disease outcome.
Plaque assays were performed to determine the concentration of
infectious virus for 65 tissues. Viral load was observed consistently
in 19 tissues from various organ systems. No virus could be detected
Fig. 3. Plaque reduction neutralizing titer 50%. Longitudinal analysis of the averages of
the PRNT50. The red line represents the daily average of survivors; the black line repre-
sents the daily average of the non-survivors. The bars indicate the standard deviation.
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developed the highest viral titers were the lymphoid, hematopoietic,
circulatory, renal, endocrine, and gastrointestinal systems (Fig. 8B).
Analysis of the data suggested a temporal change in virus distribution
with NHPs that succumbed prior to and including day 12 post inocu-
lation (7/14 NHPs) demonstrating higher concentrations of live virus
in more tissues than NHPs that succumbed past day 12 which only
had detectable virus in lung, duodenum, brain and bone marrow; in-
dicating that NHPs were able to reduce viral load in the tissues, but
developed other complications induced by SHFV. One such complica-
tion is the onset of bacteremia which was statistically associated with
lethal disease (p=0.0036) by Fisher's Exact Test. Four of eight NHPs
that succumbed prior to and including day 12 post inoculation and
6/6 that succumbed after day 12 were bacteremic based on blood cul-
ture at necropsy and histopathological evaluation suggesting a coin-
fection that may have exacerbated SHFV induced disease.
Discussion
The main purpose of this study was to establish SHFV infection of
NHPs as a suitable BSL-2 model of viral hemorrhagic fevers in humansTable 5
Cytokines and chemokines.
Cytokine/chemokine Group Mean day of cytokine peak (range) Mea
IL-1-ra
Survivor 3.78 (2–8)
Non-survivor 8.06 (2–16)
IL-6
Survivor 3.56 (2–16)
Non-survivor 9.69 (2–19)
IL-8
Survivor 9 (2–21)
Non-survivor 4.88 (0–15)
IL-18
Survivor 3.3 (2–4)
Non-survivor 3 (2–4)
IFN-γ
Survivor 5.56 (2–6)
Non-survivor 4.06 (2–8)
MCP-1
Survivor 6.4 (2–12)
Non-survivor 5.75 (2–16)
RANTES
Survivor 11.11 (6–21)
Non-survivor 5.75 (0–10)
VEGF
Survivor 11.56 (4–36)
Non-survivor 5.75 (0–15)
a Out of range.and deﬁne factors associated with disease outcome. Our data support
that SHFV LVR induces a viral hemorrhagic feverwith similar characteris-
tics as other hemorrhagic fever viruses. Clinical signs of SHFV infection
such as edema, petechial rash and coagulopathywere similar to those ob-
served in both human cases andNHPmodels of EBOV,MARV, CCHFV, and
LASV (Carneiro et al., 2007; Cummins, 1991; Feldmann and Geisbert,
2011; Leblebicioglu, 2010). As in ﬁlovirus and arenavirus infections, en-
dothelial cells appear to be infected and may play a role in the develop-
ment of coagulopathy (Hensley and Geisbert, 2005; Kunz, 2009).
Monocytes/macrophages also appear to be infected by SHFV, similar to
EBOV, MARV, and LASV infections (Lewis et al., 1989; Lukashevich et al.,
1999; Stroher et al., 2001). Additionally, the encephalitis andmyelitis ob-
served is similar to cases of convalescent human hemorrhagic viral dis-
ease (Solbrig and Naviaux, 1997; Walker et al., 1982).
SHFV-induced disease was characterized clinically by petechial rash,
edema, perineum hemorrhage, epistaxis, weight loss, and splenomegaly.
Hematology indicated evidence of DIC with increases in aPTT, PT, FDP,
and decreases in platelet counts, hematocrits, and hemoglobin concen-
trations. Gross necropsy ﬁndings included myocardial, pyloric junction,
and terminal colon hemorrhage, splenomegaly, and lymphadenopathy.
Histopathologic analysis supported clinical ﬁndings with lesions that
were indicative of active disease in the heart, kidneys, liver, lung,
lymph nodes, spleen, thymus, and CNS. The incidence of lymph nodes
with lymphadenitis, lymphoid depletion, and lymphocytolysis, splenitis
with lymphoid depletion, and thymocyte depletion with necrosis and
mineralization, was signiﬁcantly increased in non-survivors compared
to survivors indicating that disease in these organs is associated with a
fatal outcome. Conversely, the incidence of lymphoid hyperplasia oc-
curred with a signiﬁcantly greater incidence in survivors compared
to non-survivors indicates that survivors ultimately developed an
effective immune response to viral infection. This ﬁnding indicates
that intervention aimed at supporting the immune response may
help aid survival after infection of VHFs. Assessment of viral load fur-
ther supported the role of the lymphoid and circulatory systems in
disease progression. Based on clinical and histopathological disease
presentation and organ systems affected we feel that further investi-
gation of SHFV and comparison to other VHFs may identify mecha-
nisms of disease shared with other VHFs that may lead to broad
spectrum therapeutics.n peak cytokine concentration (pg/ml) (range) Peak fold change from day zero
1309.59 (379.73–4994.85) 329.75
2409.07 (337.98–7386.03) 20419.68
97.85 (20.13–434.29) 80.93
1519.51 (72.19–9101.49) 1149.05
708.06 (135.22–1969.26) 9.84
847.25 (185.27–5338.66) 9.84
2681.25 (418.17–8541.02) 881.83
4004.654 (985.98–10742.16) 2303.45
106.63 (49.39–217.92) 46.28
169.57 (37.32–588.23) 70.81
2797.70 (526.29–4826.65) 31.79
4140.10 (1581.9–5689.92) 40.07
150095.5 (25402.41–150095.5) 30.40
66696.84 (6222.8–OORa High) 16.64
288.523 (96.72–1355.71) 63.68
170.96 (11.35–500.43) 46.79
Table 6
Summary of histopathological ﬁndings.a
Organ Major ﬁnding Survivor
(incidence (%))
Non-survivor
(incidence (%))
Signiﬁcant difference in
incidence by Fisher's
Exact Test (p-value)
Lung, kidney, liver, heart, GI tract Bacteremia 1/9 (11%) 12/16 (75%) 0.0036
CNS Meningitis/encephalitis/myelitis 4/9 (44%) 9/16 (56%) 0.6882
Heart Myocarditis 9/9 (100%) 15/16 (94%) 1.0000
Kidney Interstitial nephritis 9/9 (100%) 11/16 (69%) 0.1225
Liver Necrotizing hepatitis 3/9 (33%) 6/16 (38%) 1.0000
Lung Interstitial pneumonia ﬁbrin, edema 9/9 (100%) 11/16 (69%) 0.1225
Lymph node Lymphoid hyperplasia 9/9 (100%) 2/16 (13%) b0.0001
Lymph node Lymphadenitis/lymphoid 0/9 (0%) 12/16 (75%) b0.0001
Depletion/lymphocytolysis
Spleen Lymphoid hyperplasia 7/9 (78%) 1/16 (6%) b0.0001
Spleen Splenitis/lymphoid depletion 0/9 (0%) 14/16 (88%) b0.0001
Thymus Thymocyte depletion with necrosis
and mineralization
0/9 (0%) 14/16 (88%) b0.0001
a Criteria evaluated at gross necropsy of all subjects. Survivors were necropsied at end of study on day 36.
Fig. 4. Select H&E and IHC from non-surviving SHFV infected NHPs. A. Heart: Non-suppurative myocarditis (20×) B. Necrotizing hepatitis. C. Interstitial Nephritis. D. Interstitial
pneumonia with thrombus (arrow). E. Abscess of the testis (arrow).
135R.F. Johnson et al. / Virology 421 (2011) 129–140A second goal of this study was to identify host factors statistically as-
sociated with lethal disease. Backwards matched longitudinal analyses
implicated increases inAST, ALT, ALP,MCP-1, IL-6 and aPTT, anddecreases
in ALB concentrations associated with progression to lethal disease. Al-
though the serum chemistry analyteswere associatedwith lethal disease,
these analyte changes are not speciﬁc to one organ or organ system. As
such, these datamay serve as a predictor formore severe disease and pro-
vide a clinical measure that could be easily assessed to evaluate the effec-
tiveness of treatment strategies in real time. Cytokines and other
biomarkers such as aPTT that are associated with lethal disease and are
also associated with speciﬁc host processes (inﬂammation and clotting)
provide targets to further identify host responses leading to severe dis-
ease and possibly aid in survival. For example, treatments targeting the
coagulation cascademayhelp improve survival as has beendemonstrated
for activated protein C treatment of Ebola virus infections of non-human
primates (Hensley et al., 2007).
Similar to a recent study of human survivors and non-survivors
infected with Ebola virus Zaire, MCP-1 and IL-6 were also associatedwith lethal outcome (Wauquier et al., 2010) indicating the utility of the
SHFV model for studying the involvement of the cytokine response in
VHF pathogenesis. In fact, concentrations and combinations of IL-6, IL-8,
IL-18, IFNγ, RANTES, andMCP-1may support a pro-coagulative state. Al-
though high MCP-1 concentrations have been shown to result in endo-
thelial cell contraction via RhoA signaling (Deshmane et al., 2009), no
evidence of endothelial contraction could be found by TEM in our
study, perhaps because the samples were collected at necropsy instead
of periodically through disease progression. Another possibility is that
DIC and infarction are responsible for the observed endothelial cell necro-
sis. IL-6 has been demonstrated to increase tissue factor expression on
monocytes, macrophages, and endothelial cells, (Levi, 2010) thereby ini-
tiating coagulation. We hypothesize that in conjunction with endothelial
cell disruption, the synergistic effect of IL-6, IL-8, IL-18, IFNγ, RANTES, and
MCP-1 could trigger and/or perpetuate the clotting cascade resulting in
the observed consumptive coagulopathy. For example, once the clotting
cascade is initiated by viral induced endothelial cell death the clotting
cascade expands due to increased endothelial cell death as virus
Fig. 6. Select H&E and IHC of cerebrum from SHFV infected NHPs that survived. A. Encephalitis with perivascular cufﬁng (arrow) B. IHC demonstrating SHFV positive endothelial
cells (arrow) with encephalitis.
Fig. 5. Select H&E and IHC of lymphoid tissue from non-surviving SHFV infected NHPs. A. Thymocyte depletion with necrosis and mineralization B. Lymphadenitis with lymphoid
depletion and lymphocytolysis C. Splenitis with lymphoid depletion D. IHC demonstrating SHFV antigen positive macrophages.
136 R.F. Johnson et al. / Virology 421 (2011) 129–140disseminates causing an increase in the concentrations of the pro-coagu-
lative cytokines. The expansion of the clotting cascade causes thrombin
concentrations to increase, resulting in upregulation of MCP-1, IL-6, and
other pro-inﬂammatory cytokines via PARs signaling within endothelial
cells and macrophages (Charo and Taubman, 2004; Huerta-Zepeda et
al., 2008; van der Poll et al., 2011). The end result is an exacerbation of
the coagulopathy. Further experimentation is necessary to delineate the
role of MCP-1, IL-6, other cytokines, thrombin, and PARS signaling in
the development of hemorrhagic disease.
Previously, Shevtsova et al. were able to demonstrate SHFV antigen
in vascular endothelial cells by immunoﬂuorescence (Shevtosova et al.,
1975), a ﬁnding supported by our data. Infection of endothelial cells and
monocytes/macrophages as targets for infection by SHFV was sup-
ported by TEMand IHCﬁndings and is similar to that seen in other hem-
orrhagic fever virus infections (Geisbert et al., 2003b; Kunz, 2009;
Lukashevich et al., 1999; Wahl-Jensen et al., 2005). It has been hypoth-
esized that lytic endothelial cell infection contributes to hemorrhagic
disease by triggering coagulation via exposure of endothelial collagen
as endothelial cells are destroyed (Feldmann and Geisbert, 2011). Ourdata suggest that the infection and destruction of endothelial cells initi-
ated a coagulopathy, possibly by exposure of the endothelial collagen
and induction of IL-6,MCP-1, and other cytokines. Changes in the vascu-
lar permeability would aid the dissemination of SHFV via infected
monocytes and macrophages. Immunohistochemistry demonstrated
the presence of SHFV antigen, and TEM demonstrated intracytoplasmic
paracrystalline arrays of viral protein in endothelial cells. TEM also indi-
cated that hepatic and splenic macrophages were infected by SHFV.
SHFV targeting of these cells suggests that infection in both the spleen
and liver could result in a release of pro-inﬂammatory cytokines that
would likely alter organ function and vascular permeability.
Another major ﬁnding from our study was the high incidence of bac-
teremia that was signiﬁcantly associated with lethal disease. Of the 16
NHPs that succumbed to infection, 12 developed secondary bacterial in-
fections and 1/9 non-survivors were found to be bacteremic by the end
of the study. The secondary bacterial infection ﬁndings in conjunction
with the observed immunosuppression and histopathological analysis
suggest that study animals developed initial experimental simian hemor-
rhagic fever followed by onset of bacteremia which exacerbated disease.
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Fig. 7. Transmission electron microscopy of non-surviving SHFV-infected NHPs. A) Sinusoidal endothelial cell degeneration (*) in the spleen. B) Intracytoplasmic paracrystalline
arrays of viral protein within a hepatic macrophage. C) Viral particles within the cytoplasm of a splenic macrophage (white arrow). D) Intracytoplasmic paracrystalline arrays of
viral protein within an endothelial cell in the brain (white arrow).
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reported previously (Allen et al., 1968; Renquist, 1990) but systematic
study of the role of co-infection during SHFV or any other VHF has not
been reported. Given the similar clinical presentation and tissue and
cell tropism that SHFV shares with other hemorrhagic fever viruses, it
is possible that the immunosuppression of the host during the course
of the disease predisposes the subject to opportunistic pathogens. A
similar phenomenon could be occurring in human VHFs and case deﬁ-
nition possibly under-represents co-infections in the course of disease.
Follow up studies in animal models may suffer a similar same fate be-
cause the onset of bacteremia may provide grounds for exclusion of
study data and the co-infection relegated to an unintended break in
procedure. Bacterial infections as a normal, complicating occurrence
of human VHF disease is supported by secondary bacterial infec-
tions for Junín, Ebola, and hemorrhagic orthopoxvirus infections
(Beer et al., 1999; Green et al., 1987; Kempton and Parsons, 1920;
Johnson et al., 2011). Further study of SHFV may yield a better un-
derstanding of the contribution of secondary bacterial infections
to VHF pathogenesis.
SHFV infection results in a disease similar to other viral hemor-
rhagic fevers. As such, this BSL-2 pathogen provides a model with
which to study viral hemorrhagic disease without the constraints of
BSL-4 containment and Select Agent restrictions. Key similarities be-
tween SHFV and other hemorrhagic fever infections include coagulo-
pathy, upregulation of pro-inﬂammatory cytokines, involvement of
the bone marrow, spleen, lymphoid, and hepatic systems and high
mortality rates (64%). Further development of SHFV as a model for
hemorrhagic disease may provide insights into the pathogenesis of
many other hemorrhagic fever viruses.Materials and methods
Cells and virus
SHFV strain LVRwas initially obtained fromATCC by P.B. Jahrling and
passaged 3 times on BSC-1 cells, passaged 1 additional time on MA104
cells followed by propagation in MA104 cells for stock generation:
virus was isolated by three rounds of freeze–thaw cycles followed by
low speed centrifugation and titration on BSC-1 cells. Virus stocks were
tested for sterility by blood agar streak, mycoplasma contamination
using Mycosensor (Agilent Technologies Santa Clara CA), endotoxin
levels by limulus test (Endosafe-PTS Charles River, Wilmington MA
01887)), and cross contamination with other laboratory viruses by PCR
(vaccinia and cowpox). Only stocks thatwere negative by the above test-
ing were used for NHP studies.
Inoculation of NHPs
Twenty-ﬁve Rhesus macaques of Chinese and Indian origin were in-
cluded in the study: 8 females and 17males with weights ranging from
3.97 kg to 7.91 kg. Prior to study inclusion, NHPswere given a complete
physical and screened for antibodies to SHFV, simian retrovirus (SRV),
and simian T-lymphotrophic virus (STLV) and only negative NHPs
were included. Inoculawere diluted in sterile PBS and injected intramus-
cularly in the quadriceps of the right leg. This study was a compilation of
3 independent experiments. The ﬁrst study was a pilot with n=3 at
5000 PFU of SHFV, the second study included 4 groups of 3 NHPs with
doses of SHFV ranging from50 PFU to 50,000 PFU, the third study includ-
ed 2 groups of 5 with doses of 50,000 and 500,000 PFU. NHPs were
Fig. 8. Viremia and tissue viral load of SHFV infected NHPs. A. Mean virus replication for
survivors and non-survivors determined by plaque assay on whole blood (bars repre-
sent standard deviation). B. Viral load of non-survivors was measured by plaque
assay from indicated tissue homogenates (bars represent standard deviation.). Samples
for plaque assay were not collected from 2/16 NHPs.
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exams that included blood draws, nasal and oral swabs, and urinalysis.
Moribund clinical endpoint criteria were established as follows: animals
were scored on a 0 (normal) to 10-point scale in ﬁve broad categories to
determine when clinical endpoint criteria had been reached. A score of
10 in any single category, or lower scores which add up to 10 inmultiple
categories, resulted in immediate euthanasia. The ﬁve categories were
(1) overall clinical appearance, (2) respiratory abnormalities, (3) activity
and behavior, (4) responsiveness, and (5) core body temperatures. All
animal experiments were approved by the NIAID Animal Care and Use
Committee and adhered to NIH policies.
Plaque assay
The concentration of infectious virus in tissues including whole
blood, nasal swabs, and oral swabs was assayed by plaque assay on
BSC-1 cell monolayers. Brieﬂy, serial dilutions of 10% or 20% (w/v) tissue
homogenateswere added onto BSC-1 cell monolayers, overlaid 1 h post-
adsorption with 1.8% agarose and 2× MEM (1:1) and incubated at
37 °C, 5% CO2 for 3 days. Monolayers were ﬁxed with 10% formalin for
1 h followed by removal of the agarose plugs, stained with crystal violet
(0.1% crystal violet w/v, 20% methanol v/v), and plaques were
enumerated.
Plaque reduction neutralizing titer 50%
The presence of neutralizing antibodywasmeasured by plaque reduc-
tion neutralizing titer 50% PRNT50. Serum from the periodic blood draws
were diluted 1:10 followed by serial 4 fold dilutions to 1:10,240. 30 PFU
of SHFV was incubated with serum and 1× HBSS (CellGro, Manassas,
VA) at 37 °C for 1 h. The virus–serum–HBSS mixture was then added toBSC-1 monolayers overlaid 1 h post-adsorption with 1.8% agarose and
2× MEM (1:1) and incubated at 37 °C, 5% CO2 for 3 days. Monolayers
wereﬁxedwith 10% formalin for 1 h followed by removal of the agarose
plugs, stained with crystal violet (0.1% crystal violet w/v, 20% methanol
v/v), and plaques were enumerated. The serum dilution at which the
plaque number was reduced by 50% or greater when compared to con-
trols was scored as the PRNT50 for that sample.
Serology and clinical chemistry
Complete blood counts including leukocyte differentials (CBC/diff)
were determined from blood samples collected in ethylenediaminete-
traacetic acid (EDTA)-coated blood tubes and analyzed using a Sysmex
XS1000i™ (SysmexAmerica,Mundelein, IL). Serumbiochemical analyses
were performed using a Piccolo point-of-care blood analyzer with the
Comprehensive Metabolic Panel disk (Abaxis, Sunnydale, CA) which in-
cluded assays for total protein, sodium, potassium, chloride, calcium, glu-
cose, blood urea nitrogen, alkaline phosphatase (ALP), creatine, alanine
aminotransferase (ALT), aspartate aminotransferase (AST), albumin
(ALB), bilirubin, and carbon dioxide. For coagulation studies, samples
were analyzed on a Thromboscreen 2000 (Paciﬁc Hemostasis Fisher Sci-
entiﬁc Diagnostics Middletown, VA) for activated partial thromboplastin
time (aPTT) and prothrombin time (PT). Fibrin degradation products
(FDP) were measured using the Paciﬁc Hemostasis serum FDP kit (Ther-
mo Fisher Scientiﬁc, Inc., Middletown, VA) according tomanufacturer di-
rections. Serum was collected from SST vacutainers by centrifugation of
1600×g for 10 min. Serum was aliquoted and frozen at −80 °C until
study end, and then assayed by latex agglutination. Sampleswere diluted
andmixed in equal volumes with the latex reagent on the test cards pro-
vided in the kit. Test cards were gently rocked for 3 min at room temper-
ature, and agglutination results were recorded for each dilution. Results
were reported for the highest dilution that yielded a positive agglutina-
tion response.
Cytokine and chemokine quantiﬁcation
The concentrations of 23 cytokines and chemokines in NHP sera
were analyzed using the Millipore Non-Human Primate Cytokine
Panel Premixed 23-plex (Millipore, Billerica MA). Brieﬂy, undiluted
EDTAplasma sampleswere transferred to a 96-well plate and incubated
with beads coated with antibodies directed against each cytokine or
chemokine. For the RANTES analysis, a 1:100 dilution was made for
each sample. Following incubation, the beads were washed, incubated
with anti-cytokine and chemokine antibodies, and incubated with
Streptavidin-R-phycoerythrin (SAV/RPE). Beads were assayed on the
Bioplex 100 System (Bio-Rad, Hercules CA). Cytokines were included
for comparison when there was a two-fold or greater change above
background detection of the manufacturer supplied standards.
Necropsy and histology
Complete necropsies were performed either when the NHP met the
study endpoint criteria for euthanasia or at study end (day 36). Tissue
samples were collected from all major organs for histopathological anal-
ysis and determination of viral load. Histology sampleswere ﬁxed by im-
mersion in 10% phosphate-buffered formalin, parafﬁn-embedded, and
sectioned and afﬁxed to a glass slide. Specimens were then stained
with hematoxylin and eosin (H&E), rinsed, and examined via light mi-
croscopy by two veterinary pathologists (DRR, SY).
Immunohistochemistry (IHC) was performed on 5 μm thick sections
of formalin-ﬁxed parafﬁn embedded tissue using the Bond automated
immunostainer (Leica Microsystems, Bannockburn, IL). Parafﬁn was re-
moved with xylene, and the sections were rehydrated in a series of alco-
hol washes. Heat-induced epitope retrieval was performed using citrate
(pH 6.0) at 100 °C for 25 min. SHFV antigenwas identiﬁed immunohisto-
chemically using a biotinylated mouse anti-SHFV polyclonal antibody
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CLVNLRKYGWQTKNK by Genscript (Piscataway NJ)) incubated for
15 min at room temperature. Primary antibodywas localizedwith horse-
radish peroxidase and diaminobenzidine substrate. Antibody speciﬁcity
to SHFV was performed by IHC analysis using the SHFV polyclonal anti-
body against tissues from historical, normal uninfected NHP controls. In
controls to determine background IHC staining, buffer was used in
place of the primary antibody. Sections were counterstained with hema-
toxylin and examined by light microscopy by veterinary pathologists.
Electron microscopy
For thin-section electron microscopic evaluation, dissected tissues
were immediately ﬁxed in 2.5% glutaraldehyde and 2.0% paraformalde-
hyde, in Millonig's sodium phosphate buffer (Tousimis Research, Rock-
ville, MD), for 72 h. Fixed tissue samples were rinsed repeatedly in
Millonig's buffer and post-ﬁxed in 1.0% osmium tetroxide in the same
buffer. Following rinsing steps in ultrapure water and en bloc staining
with 2.0% uranyl acetate, the samples were dehydrated in a series of
graded ethanols, inﬁltrated, and embedded in DER-736 plastic resin
(Tousimis Research, Rockville, MD). Embedded blocks were sectioned
using a Leica EM UC7 Ultramicrotome. Sections between 50 and 70 nm
were collected on 200 mesh copper grids and post-stained with Rey-
nold's lead citrate. The tissue sectionswere examined by a veterinary pa-
thologist (JAC) using a FEI Tecnai Spirit Twin transmission electron
microscope operating at 80 kV.
Statistical analysis
Survival analyses comparing mortality by inoculation dose and
gender were performed using the log-rank test. Hypothesis tests on
incidence rates were conducted in Stata 9.0 using Fisher's Exact Test
values were considered signiﬁcant when p≤0.01.
A total of 60 parameterswere assessed during the course of the study.
Of these 60, ten parameterswere considered subjective (relied on clinical
experience i.e. spleen palpation) or did not generate numerical values,
two yielded no usable data (nasal and oral swab titers), six were cyto-
kines that did not increase over baseline for any NHP in any dose group,
and seven were serum chemistry analytes that did not appreciably
change. The remaining 35 parameters (AST, aPTT, ALP, MCP-1, ALT, IL-6,
neutrophil counts, platelet count, hematocrits, hemoglobin concentra-
tions, IFNγ, viremia, IL-15, PT, VEGF, IL-5, creatinine, lymphocyte count,
sCD40L, GM-CSF, IL-12, total bilirubin, TGFα, IL-2, G-CSF, total protein,
IL-8, leukocyte count, monocyte count, IL-18, albumin, MIP-1α, TNFα,
IL-1ra, and RANTES) were considered relevant to disease progression
for statistical analysis. Because of themultiple comparisons, the following
p-values for test parameters were considered to be supportive of statisti-
cal signiﬁcance for an associationwith survival status when p≤0.01, and
suggestive of statistical signiﬁcancewhen 0.01≤p≥0.05. Also, due to the
possible correlation between many of the factors, such as cytokines and
clotting factors, the p-values was selected a priori rather than the Bonfer-
roni method, which is known to be conservative.
To identify factors that may associate with disease severity, changes
from baseline were evaluated according to BMLA. The trajectories for a
given subject were summarized by the area under the curve (AUC), as
this characterizes both the intensity and duration of exposure. Secondary
analyses summarized trajectories according to the rate of change (as
represented by the slope of a line, over a time period during which
change was captured by a line), and the maximum observed value. To
compare these summaries between survivors and non-survivors, BLA
compares summary measures over similar time intervals for survivors
and non-survivors. Survivors and non-survivors are matched and the
summary measures (e.g., AUC) are computed over the same time inter-
val for each pair. The differences in the AUC are computed between the
pairs and a paired t-test is performed. Because there are many possible
pairings, this process is repeated 1000 times, and a common p-value is
obtained using the inverse normal p-value averaging (Dodd et al., 2011).Acknowledgments
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